MX372787B - Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. - Google Patents

Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Info

Publication number
MX372787B
MX372787B MX2015009142A MX2015009142A MX372787B MX 372787 B MX372787 B MX 372787B MX 2015009142 A MX2015009142 A MX 2015009142A MX 2015009142 A MX2015009142 A MX 2015009142A MX 372787 B MX372787 B MX 372787B
Authority
MX
Mexico
Prior art keywords
prevention
treatment
factor receptor
fgr3
polypeptide
Prior art date
Application number
MX2015009142A
Other languages
English (en)
Other versions
MX2015009142A (es
Inventor
Elvire Gouze
Original Assignee
Inst Nat Sante Rech Med
Univ Toulouse 3 Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Toulouse 3 Paul Sabatier filed Critical Inst Nat Sante Rech Med
Publication of MX2015009142A publication Critical patent/MX2015009142A/es
Publication of MX372787B publication Critical patent/MX372787B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un polipéptido de receptor 3 del factor de crecimiento de fibroblastos soluble (sFGFR3) aislado, para usarse en la prevención o el tratamiento de una enfermedad esquelética relacionada a FGFR3 en un sujeto con necesidad del mismo, en donde el polipéptido sFGFR3 aislado comprende al menos 325 aminoácidos consecutivos de la región extracelular del receptor FGFR3, comprende un dominio intracelular del FGFR3 y carece de secuencias de aminoácidos que corresponden al dominio transmembrana de FGFR3, y en donde opcionalmente el polipéptido sFGFR3 está fusionado a un polipéptido heterólogo, formado así una inmunodhesina sFGFR3.
MX2015009142A 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico. MX372787B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
PCT/EP2014/050800 WO2014111467A1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (2)

Publication Number Publication Date
MX2015009142A MX2015009142A (es) 2015-11-06
MX372787B true MX372787B (es) 2020-07-03

Family

ID=48289519

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009142A MX372787B (es) 2013-01-16 2014-01-16 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
MX2019013857A MX2019013857A (es) 2013-01-16 2015-07-15 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019013857A MX2019013857A (es) 2013-01-16 2015-07-15 Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.

Country Status (19)

Country Link
US (5) US20150344855A1 (es)
EP (2) EP3736285A1 (es)
JP (3) JP2016506914A (es)
KR (3) KR20160002681A (es)
CN (1) CN105121464B (es)
AU (2) AU2013373679A1 (es)
CA (2) CA2898415A1 (es)
DK (1) DK2945967T3 (es)
EA (2) EA201591324A1 (es)
ES (1) ES2796743T3 (es)
HU (1) HUE049556T2 (es)
IL (2) IL239810A0 (es)
MX (2) MX372787B (es)
PE (1) PE20151664A1 (es)
PL (1) PL2945967T3 (es)
PT (1) PT2945967T (es)
SG (2) SG11201505488XA (es)
SI (1) SI2945967T1 (es)
WO (2) WO2014111744A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
SI3242888T1 (sl) 2015-01-07 2021-07-30 Pfizer Inc. Topne vabe FGFR3 za zdravljenje motenj rasti skeleta
KR101894022B1 (ko) * 2016-04-25 2018-08-31 장부다 Vr 공간을 제공하는 디바이스를 이용한 결제 방법 및 그 디바이스
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
BR112020005459A2 (pt) * 2017-09-20 2020-09-29 Pfizer Inc. tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3)
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
EP1342476A3 (en) * 1995-06-12 2003-09-17 Yeda Research And Development Co. Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
AU2001276842B2 (en) 2000-06-28 2007-04-26 Glycofi, Inc. Methods for producing modified glycoproteins
WO2002050246A2 (en) * 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
IL156495A0 (en) * 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
DK1718756T3 (da) * 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
US8962556B2 (en) 2006-09-28 2015-02-24 Prochon Biotech Ltd. FGF-2 variants having N-terminal deletions and increased receptor selectivity and uses thereof
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
BRPI0916904A2 (pt) 2008-08-04 2016-10-11 Fiveprime Therapeutics Inc polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
EP3702371B1 (en) 2009-03-25 2022-11-02 Genentech, Inc. Anti-fgfr3 antibodies and methods using same
CN101585866B (zh) * 2009-07-02 2011-10-05 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
LT2498799T (lt) 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
WO2011084711A2 (en) * 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
EP2523679A4 (en) 2010-01-14 2013-07-24 Univ Yale Inc RECEPTORT SYROSINE KINASE (RTK) INHIBITOR AND ITS USE METHOD
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US9266939B2 (en) * 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
KR101828828B1 (ko) 2011-10-24 2018-03-29 할로자임, 아이엔씨 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013295805B2 (en) 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014018841A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
AU2015209131B2 (en) 2014-01-24 2020-06-25 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
SI3242888T1 (sl) 2015-01-07 2021-07-30 Pfizer Inc. Topne vabe FGFR3 za zdravljenje motenj rasti skeleta
RU2751483C2 (ru) 2016-07-07 2021-07-14 Пфайзер Инк. Полипептиды, являющиеся растворимыми рецепторами 3 фактора роста фибробластов (sfgfr3), и пути их применения
BR112020005459A2 (pt) 2017-09-20 2020-09-29 Pfizer Inc. tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3)

Also Published As

Publication number Publication date
US11814654B2 (en) 2023-11-14
HUE049556T2 (hu) 2020-09-28
CN105121464A (zh) 2015-12-02
JP2019107006A (ja) 2019-07-04
IL239996A0 (en) 2015-08-31
CA2896978A1 (en) 2014-07-24
US20210032607A1 (en) 2021-02-04
JP6995069B2 (ja) 2022-02-04
JP2016506914A (ja) 2016-03-07
KR20210054026A (ko) 2021-05-12
US10724014B2 (en) 2020-07-28
AU2014206844A1 (en) 2015-07-16
MX2019013857A (es) 2020-01-20
PT2945967T (pt) 2020-05-28
WO2014111744A1 (en) 2014-07-24
SG11201505488XA (en) 2015-08-28
US11702642B2 (en) 2023-07-18
EA201591055A1 (ru) 2016-04-29
EP2945967A1 (en) 2015-11-25
DK2945967T3 (da) 2020-07-13
PL2945967T3 (pl) 2020-11-16
KR20150122136A (ko) 2015-10-30
US20150344855A1 (en) 2015-12-03
KR102249454B1 (ko) 2021-05-07
WO2014111467A1 (en) 2014-07-24
PE20151664A1 (es) 2015-11-28
EP2945967B1 (en) 2020-04-15
HK1217959A1 (zh) 2017-01-27
KR20160002681A (ko) 2016-01-08
US20200199545A1 (en) 2020-06-25
MX2015009142A (es) 2015-11-06
CN105121464B (zh) 2021-05-07
SG11201505140XA (en) 2015-07-30
SI2945967T1 (sl) 2020-10-30
CA2898415A1 (en) 2014-07-24
EA201591324A1 (ru) 2016-01-29
EP3736285A1 (en) 2020-11-11
AU2013373679A1 (en) 2015-08-13
IL239810A0 (en) 2015-08-31
JP2016506912A (ja) 2016-03-07
US20150353624A1 (en) 2015-12-10
ES2796743T3 (es) 2020-11-30
US20210032608A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX372787B (es) Un polipeptido receptor del factor de crecimiento de fibroblasto soluble 3 (fgr3) para el uso en la prevencion o tratamiento de trastornos de retraso de crecimiento esqueletico.
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
MX2017014375A (es) Moduladores del ccr2.
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
CO6791571A2 (es) Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos
JO3475B1 (ar) ناهضات مستقبل سوماتوستاتين نوع فرعي 4 (sstr4) جديدة
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
MX390084B (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2018001370A1 (es) Derivados novedosos de diamino piridina
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
PH12022551548A1 (en) Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration